Corpusense

Gilead Sciences (GILD) earnings call transcript summary & sentiment

Last call Tue 4 Aug 2026·Next Thu 29 Oct 2026

Our read on the 4 August 2026 earnings call

Overall tone: Positive

Overall tone

Positive

Executive Summary

Gilead Sciences reported strong second-quarter performance with base business revenue expanding 10% year-over-year to $7.6 billion, driven by double-digit growth in its core HIV franchise and Trodelvy.

Core Signals

Revenue Growth & Demand: Base business sales expanded 10% year-over-year to $7.6 billion behind double-digit growth in HIV and Trodelvy, partially offset by cell therapy declines.

Bullish Signals

Base business sales grew 10% YoY with HIV accelerating to 12% growth, supporting a raised full-year HIV sales outlook of 9% to 10%.

Risk Signals

Cell therapy revenue declined 14% year-over-year due to competitive pressure, causing management to lower full-year cell therapy guidance to a mid-teens percentage decline.

Q&A Signals

Repeated analyst topics: Analysts repeatedly probed PrEP growth drivers, Yes2Go persistency metrics, product cannibalization risks across oral and injectable regimens, and ACA regulatory impacts.

Key Investor Debate

The primary investor debate centers on Gilead's ability to maintain top-line momentum as its HIV franchise transitions from legacy daily oral therapies to long-acting injectables and weekly switch regimens.

Analyst Takeaway

Management's confident presentation and underlying volume acceleration underscore commercial strength in core virology and oncology assets.

Those are the opening lines. The full read covers the whole earnings transcript: every bullish and bearish signal, what analysts pressed hardest on, and where management answered vaguely — each with the quote behind it. Every line sourced.

See the full Earnings Highlight

Themes across Gilead Sciences and the Health Care sector

Analyse a theme over quarters — what's brand new, what's being talked about more, and what is spreading to more companies across the sector.

Unlock themes

Ask about Gilead Sciences's earnings, or other S&P 500 earnings calls

Ask across the corpus, instead of reading one call at a time. Scope it to Gilead Sciences, its sector, or every name we cover — plain English, no operators — and answers come back structured: a summary, the drivers, and a read on each company.

"What did Gilead Sciences say about margins, and did the framing change from last quarter?"

"Did Gilead Sciences's management walk back any full-year guidance, and how did they frame it?"

"Where did Gilead Sciences avoid answering on capital allocation?"

Unlock search

Earnings call history & sentiment

Every one at 16:30 ET, after the close.

Date Day Period Corpusense read
2026-08-04Tuesday2026 Q3Positive
2026-05-07Thursday2026 Q2Positive
2026-02-10Tuesday2026 Q1Positive
2025-10-30Thursday2025 Q4—
2025-08-07Thursday2025 Q3—
2025-04-24Thursday2025 Q2—
2025-02-11Tuesday2025 Q1—

Earnings calls across Biotechnology

The companies Gilead Sciences is read alongside. Each has its own earnings call dates and sentiment.

ABBVAbbVieAMGNAmgenBIIBBiogenINCYIncyteMRNAModernaREGNRegeneron PharmaceuticalsVRTXVertex Pharmaceuticals

Gilead Sciences is one of the S&P 500 companies we track

Sentiment analysis on any single earnings call, themes building across a sector, and search across every company and quarter — each claim linked back to the passage it came from.

Create a free account See the full calendar Plans & pricing